MindRank Pharma Named to KPMG China's Top 50 Biotech Innovation Leaders and Advances Toward IPO

The current KPMG selection, branded as the "China Biotech Innovation Leadership List" with a refreshed and upgraded identity, builds on the forward-looking insights of the industry from the previous two editions. By fully leveraging the advantages of industrial clusters and policy resources, it further supports the biotech sector in building a globally competitive highland for pharmaceuticals and health industry development, continuously empowering the high-quality growth of the biopharmaceutical industry.

This list continues the consistent and rigorous selection criteria of KPMG China, evaluating the leading nature of technology and product lines, the richness of the product pipeline and the proportion of original products, the background of the core management and R&D teams, industrialization prospects, capital market activity, and financial health.Six Dimensions,Duration8 months,Finally, the selections cover biopharmaceuticals, medical devices, cell therapy and gene therapy, in vitro diagnostics, AI drug discovery, pharmaceutical outsourcing organizations, and innovation in traditional Chinese medicine.Leading enterprises in seven major细分fields.

Targeting the inefficient dilemma of traditional drug development, which is like "finding a needle in a haystack," MindRank's one-stop AI pharmaceutical platform can reduce preclinical R&D cycles and costs by 50% or more, systematically increasing the success rate of early-stage R&D. Currently,"MindRank"The first self-developed GLP-1RA small molecule oral drug MDR-001 has successfully advanced to Phase IIb clinical research, and the new anti-tumor drug MRANK-106 has received clinical approval from the U.S. FDA.Based on the continuous innovation and iteration of the AI pharmaceutical system, the team will accelerate the advancement of innovative drug development in the fields of metabolism and oncology, enabling better drugs to benefit the public sooner.

Original link:

KPMG China Three Regions Unveil New Ranking: Decoding the Global Competitiveness of Biotech Innovation Leaders

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby enabling more diseases to be treatable and allowing more lives to regain health.

The company owns a self-developed, world-leading industrial-grade one-stop AI-driven innovative drug R&D platform, including the knowledge graph-based data mining platform PharmKG™, the protein dynamic simulation and structure prediction platform Molecule Dance™, and the one-stop AI drug design platform Molecule Pro™. The company’s AI pharmaceutical solutions were recognized by the authoritative European and American institution Deep Pharma Intelligence as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020." In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune's IMPACT Companies list as one of "China's most socially impactful startups."

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai